Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Institute for Clinical and Experimental Medicine
Institute for Clinical and Experimental Medicine
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Massachusetts General Hospital
Massachusetts General Hospital
Therakos LLC
M.D. Anderson Cancer Center
Incyte Corporation
Emory University
University of California, San Francisco
Helse Møre og Romsdal HF
Massachusetts General Hospital